41 – 50 of 2076
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Cognitive Safety is Largely Ignored in Clinical Drug Trials : A Study of Registered Study Protocols
- Contribution to journal › Article
-
Mark
The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis
- Contribution to journal › Article
-
Mark
Structure-function analysis of time-resolved immunological phases in metabolic dysfunction-associated fatty liver disease (MASH) comparing the NIF mouse model to human MASH
- Contribution to journal › Article
-
Mark
Sevuparin strongly reduces hepcidin expression in cells, mice, and healthy human volunteers
- Contribution to journal › Article
- 2023
-
Mark
Models and biomarkers of motor and neuropsychiatric complications in Parkinson’s disease
(2023) In Lund University, Faculty of Medicine Doctoral Dissertation Series
- Thesis › Doctoral thesis (compilation)
-
Mark
Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?
- Contribution to journal › Letter
-
Mark
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor : a single- and multiple-dose first-in-human study in healthy participants
- Contribution to journal › Article
-
Mark
Recombinant α
1-Microglobulin (rA1M) Protects against Hematopoietic and Renal Toxicity, Alone and in Combination with Amino Acids, in a
177Lu-DOTATATE Mouse Radiation Model.
- Contribution to journal › Article
-
Mark
Epigenetics of methylmercury
- Contribution to journal › Article
-
Mark
Evidence for Prepulse Inhibition of Visually Evoked Motor Response in Drosophila melanogaster
- Contribution to journal › Article
